Literature DB >> 28654781

Comparison of SEC and CE-SDS methods for monitoring hinge fragmentation in IgG1 monoclonal antibodies.

Oluwatosin O Dada1, Romesh Rao2, Natalie Jones2, Nomalie Jaya2, Oscar Salas-Solano2.   

Abstract

Fragmentation of monoclonal antibodies is a critical quality attribute routinely monitored to assess the purity and integrity of the product from development to commercialization. Cleavage in the upper hinge region of IgG1 monoclonal antibodies is a common fragmentation pattern widely studied by size exclusion chromatography (SEC). Capillary electrophoresis with sodium dodecylsulfate (CE-SDS) is a well-established technique commonly used for monitoring antibody fragments as well, but its comparability to SEC in monitoring hinge fragments has not been established until now. We report a characterization strategy that establishes the correlation between hinge region fragments analyzed by SEC and CE-SDS. Monoclonal antibodies with elevated hinge fragments were generated under low pH stress conditions and analyzed by SEC and CE-SDS. The masses of the fragments generated were determined by LC-MS. Electrophoretic migration of the hinge fragmentation products in CE-SDS were determined based on their mass values. Comparative assessment of fragments by SEC, and CE-SDS showed similar correlation with incubation time. This study demonstrates that CE-SDS can be employed as a surrogate technique to SEC for monitoring hinge region fragments. Most importantly, combination of these techniques can be used to obtain comprehensive understanding of fragment related characteristics of therapeutic protein products.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody; CE-SDS; Electrophoresis; Fragmentation; SEC

Mesh:

Substances:

Year:  2017        PMID: 28654781     DOI: 10.1016/j.jpba.2017.06.006

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

Review 1.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

2.  Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance.

Authors:  Saori Suzuki; Hiroaki Annaka; Shota Konno; Izumi Kumagai; Ryutaro Asano
Journal:  Sci Rep       Date:  2018-11-22       Impact factor: 4.379

3.  The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.

Authors:  Ming Yi; Jing Zhang; Anping Li; Mengke Niu; Yongxiang Yan; Ying Jiao; Suxia Luo; Pengfei Zhou; Kongming Wu
Journal:  J Hematol Oncol       Date:  2021-02-16       Impact factor: 17.388

4.  Identification of a CE-SDS shoulder peak as disulfide-linked fragments from common CH2 cleavages in IgGs and IgG-like bispecific antibodies.

Authors:  Mingyan Cao; Yang Jiao; Conner Parthemore; Samuel Korman; Jiao Ma; Alan Hunter; Greg Kilby; Xiaoyu Chen
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.